β
Outcome Measurepharmacokinetics

C max

Maximum Plasma Concentration

1 Paper in Blossom

Outcome Data Across Studies

Reported results for C max across 1 study with quantitative data.

Outcome data across 1 study arm–timepoint observations
SD
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study
2025Secondary
5-MeO-DMT 12 mg(experimental)0—2.2——

Papers Using C max

Paywallindividual

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant adverse events, rapid absorption with peak plasma concentrations at 20 minutes, dose-dependent neurophysiological modulation without full psychedelic effects, and maintenance of normal cognitive and behavioral function.

Published
Journal
Neuropsychopharmacology
Authors
Beatriz, M., Millón, B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D. E., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L., Garcés, M. A., Diez, P., Albarracín, S. G., Bruno, M. A.

Quick Facts

Full Name
Maximum Plasma Concentration
Domain
pharmacokinetics
Papers Indexed
1
Unit
ng/mL
All Measures